GlassScriptPhysician profile
Lisa Thibodeaux
NPI 1417148933
$4,566.82
in general payments reported to CMS, 2019-2025
29 companies · $976 in 2025
The $976 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $535 · 2021: $460 · 2022: $416 · 2023: $794 · 2024: $1,112 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $817.18 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $792.79 | 2020-2025 | Briviact, Fintepla, Nayzilam |
| Sunovion Pharmaceuticals INC. | $478.31 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $425.47 | 2019-2025 | |
| Pfizer INC. | $313.72 | 2023-2025 | |
| Neurelis, INC. | $274.80 | 2024-2025 | Valtoco |
| Sk Life Science, INC. | $258.81 | 2022-2025 | Xcopri |
| Genzyme Corporation | $195.62 | 2020-2021 | |
| Lundbeck LLC | $116.79 | 2023-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $116.63 | 2019-2020 | |
| Eisai INC. | $100.47 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $91.49 | 2020 | |
| Vertiflex, INC. | $84.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $76.26 | 2023-2024 | Ultomiris |
| Axsome Therapeutics, INC. | $58.55 | 2025 | Symbravo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $49.62 | 2022-2023 | Onpattro |
| Ge Healthcare | $42.76 | 2021 | |
| Edw Pharma, INC. | $41.25 | 2024 | Tiglutik |
| Celgene Corporation | $33.00 | 2023 | Zeposia |
| Ani Pharmaceuticals, INC. | $24.79 | 2025 | Purified Cortrophin Gel |
| Alfasigma USA, INC. | $24.05 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.05 | 2021 | |
| Grifols USA, LLC | $23.37 | 2023 | Gamunex-C |
| Nevro Corp. | $21.38 | 2023 | Senza |
| Novartis Pharmaceuticals Corporation | $19.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $18.62 | 2019 | |
| Horizon Therapeutics Plc | $15.59 | 2023 | Uplizna |
| Boston Scientific Corporation | $13.74 | 2021 | |
| Forte Bio-Pharma LLC | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Thibodeaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.